Literature DB >> 17047193

Opposing risks of gastric cardia and noncardia gastric adenocarcinomas associated with Helicobacter pylori seropositivity.

Farin Kamangar1, Sanford M Dawsey, Martin J Blaser, Guillermo I Perez-Perez, Pirjo Pietinen, Craig J Newschaffer, Christian C Abnet, Demetrius Albanes, Jarmo Virtamo, Philip R Taylor.   

Abstract

BACKGROUND: Colonization with Helicobacter pylori is a risk factor for gastric adenocarcinoma, but the magnitude of this association and its relationship to anatomic location of the cancer, duration of follow-up, age at diagnosis, histologic subtype, and H. pylori strain differences are less clear. We conducted a prospective nested case-control study of H. pylori serology to address these questions.
METHODS: Case and control subjects were selected from the 29,133 50- to 69-year-old males recruited into the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study. At baseline, detailed demographic data and a serum sample were collected. From 1985 to 1999, 243 incident cases of gastric adenocarcinoma were diagnosed in cohort members. Serum samples from 234 case subjects (173 with noncardia gastric cancers and 61 with gastric cardia cancers) and 234 age-matched control subjects were assayed for antibodies against H. pylori whole-cell and CagA antigens. We fit conditional logistic regression models to estimate the unadjusted and adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for the association of H. pylori seropositivity, defined as seropositivity to either whole-cell or CagA antigens, with noncardia gastric and gastric cardia cancers. All statistical tests were two-sided.
RESULTS: H. pylori seropositivity was strongly associated with the risk of noncardia gastric cancer (adjusted OR = 7.9, 95% CI = 3.0 to 20.9) but was inversely associated with the risk of gastric cardia cancer (adjusted OR = 0.31, 95% CI = 0.11 to 0.89). H. pylori seropositivity rates did not vary statistically significantly by length of follow-up, age at diagnosis, or histologic subtype. A calculation of rates showed that the absolute risks of noncardia gastric and cardia gastric adenocarcinomas in the H. pylori-positive participants of this cohort would be 63 and 12 per 100,000 person-years, respectively, whereas corresponding rates in H. pylori-negative participants would be 8 and 37 per 100,000 person-years, respectively.
CONCLUSION: H. pylori is a strong risk factor for noncardia gastric cancer but is inversely associated with the risk of gastric cardia cancer. These findings bolster the hypothesis that decreasing H. pylori prevalence during the past century may have contributed to lower rates of noncardia cancer and higher rates of cardia cancer in Western countries.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17047193     DOI: 10.1093/jnci/djj393

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  124 in total

1.  Helicobacter pylori and esophageal cancer risk: a meta-analysis.

Authors:  Farhad Islami; Farin Kamangar
Journal:  Cancer Prev Res (Phila)       Date:  2008-10

2.  Prospective study of Helicobacter pylori biomarkers for gastric cancer risk among Chinese men.

Authors:  Meira Epplein; Wei Zheng; Yong-Bing Xiang; Richard M Peek; Honglan Li; Pelayo Correa; Jing Gao; Angelika Michel; Michael Pawlita; Qiuyin Cai; Xiao-Ou Shu
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-10-03       Impact factor: 4.254

3.  Multiplex H. pylori Serology and Risk of Gastric Cardia and Noncardia Adenocarcinomas.

Authors:  Ramin Shakeri; Reza Malekzadeh; Dariush Nasrollahzadeh; Michael Pawlita; Michael Pawilta; Gwen Murphy; Farhad Islami; Masoud Sotoudeh; Angelika Michel; Arash Etemadi; Tim Waterboer; Hossein Poustchi; Paul Brennan; Paolo Boffetta; Sanford M Dawsey; Farin Kamangar; Christian C Abnet
Journal:  Cancer Res       Date:  2015-09-17       Impact factor: 12.701

4.  Indigenous inequities in the presentation and management of stomach cancer in New Zealand: a country with universal health care coverage.

Authors:  Virginia Signal; Diana Sarfati; Ruth Cunningham; Jason Gurney; Jonathon Koea; Lis Ellison-Loschmann
Journal:  Gastric Cancer       Date:  2014-08-07       Impact factor: 7.370

5.  The course of gastric cancer following surgery is associated with genetic variations of the interleukin-1 receptor antagonist and interleukin-1β.

Authors:  Anke H van der Ploeg; Oliver Kumpf; Evelyn Seelow; Luis C Berrocal Almanza; Peter M Schlag; Ralf R Schumann; Lutz Hamann
Journal:  Gastric Cancer       Date:  2014-02-21       Impact factor: 7.370

6.  Fruit and vegetable consumption, Helicobacter pylori antibodies, and gastric cancer risk: A pooled analysis of prospective studies in China, Japan, and Korea.

Authors:  Tianyi Wang; Hui Cai; Shizuka Sasazuki; Shoichiro Tsugane; Wei Zheng; Eo Rin Cho; Sun Ha Jee; Angelika Michel; Michael Pawlita; Yong-Bing Xiang; Yu-Tang Gao; Xiao-Ou Shu; Wei-Cheng You; Meira Epplein
Journal:  Int J Cancer       Date:  2016-10-31       Impact factor: 7.396

Review 7.  Pre-existing diabetes mellitus increases the risk of gastric cancer: a meta-analysis.

Authors:  Jae Moon Yoon; Ki Young Son; Chun Sick Eom; Daniel Durrance; Sang Min Park
Journal:  World J Gastroenterol       Date:  2013-02-14       Impact factor: 5.742

8.  Obesity and the Incidence of Upper Gastrointestinal Cancers: An Ecological Approach to Examine Differences across Age and Sex.

Authors:  Melina Arnold; Amy Colquhoun; Michael B Cook; Jacques Ferlay; David Forman; Isabelle Soerjomataram
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-10-22       Impact factor: 4.254

Review 9.  Molecular cancer prevention: Current status and future directions.

Authors:  Karen Colbert Maresso; Kenneth Y Tsai; Powel H Brown; Eva Szabo; Scott Lippman; Ernest T Hawk
Journal:  CA Cancer J Clin       Date:  2015-08-18       Impact factor: 508.702

10.  Gastric carcinogenesis.

Authors:  Ismail Gomceli; Baris Demiriz; Mesut Tez
Journal:  World J Gastroenterol       Date:  2012-10-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.